Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo
Authors:
- Inderjeet Singh BharajInderjeet Singh Bharaj
- Ajit Singh BrarAjit Singh Brar
- Aayushi KacheriaAKAayushi Kacheria
- Karen PurewalKPKaren Purewal
- Austin SimisterASAustin Simister
- Umabalan ThirupathyUTUmabalan Thirupathy
- Palak GuptaPGPalak Gupta
- Jasraj Singh KahlonJKJasraj Singh Kahlon
- Juzer MunaimJMJuzer Munaim
- Ei Ei ThweETEi Ei Thwe
- Samer IbrahimSISamer Ibrahim
- Valerie Martinez VargasVVValerie Martinez Vargas
Preprint
- 8 September 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.Keywords
All Related Versions
This publication has 93 references indexed in Scilit:
- RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease ManagementJournal of Cardiovascular Translational Research, 2025
- Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of HealthJAMA Network Open, 2024
- Obicetrapib—the Rebirth of CETP Inhibitors?Current Atherosclerosis Reports, 2024
- Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020JAMA, 2024
- 2024 Update in Heart FailureESC Heart Failure, 2024
- Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity ManagementCurrent Atherosclerosis Reports, 2022
- Association of Lipoprotein (a) and 1 Year Prognosis in Patients with Heart Failure with Reduced Ejection FractionESC Heart Failure, 2022
- Association between lipoprotein (a) and heart failure with reduced ejection fraction developmentJournal of Clinical Laboratory Analysis, 2021
- Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney diseaseCochrane Database of Systematic Reviews, 2020
- Aldosterone antagonists for people with chronic kidney disease requiring dialysisCochrane Database of Systematic Reviews, 2018